Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: A meta-analysis

Página do item simplificado
dc.contributor.authorBaruffi, Ricardo L.R.
dc.contributor.authorMauri, A. L. [UNESP]
dc.contributor.authorPetersen, C. G. [UNESP]
dc.contributor.authorFelipe, V.
dc.contributor.authorMartins, A. M C
dc.contributor.authorCornicelli, J.
dc.contributor.authorCavagna, M.
dc.contributor.authorOliveira, J. B A
dc.contributor.authorFranco, J. G.
dc.contributor.institutionCentre for Human Reproduction Prof. Franco J
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionSanto Amaro University
dc.date.accessioned2014-05-27T11:22:21Z
dc.date.available2014-05-27T11:22:21Z
dc.date.issued2007-01-01
dc.description.abstractThis study aims to compare the efficacy of recombinant LH (rLH) supplementation for ovarian stimulation in gonadotrophin-releasing hormone-antagonist protocol for IVF/intracytoplasmic sperm injection cycles. Search strategies included online surveys of databases. The fixed effects model was used for odds ratio (OR) and effect size (weighted mean difference, WMD). Five trials fulfilled the inclusion criteria. When the meta-analysis was carried out, advantages were observed for the LH supplementation protocol with respect to higher serum oestradiol concentrations on the day of human chorionic gonadotrophin administration (P < 0.0001; WMD: 514, 95% CI 368, 660) and higher number of mature oocytes (P = 0.0098; WMD: 0.88, 95% CI 0.21, 1.54). However, these differences were not observed in the total amount of recombinant FSH (rFSH) administered, days of stimulation, number of oocytes retrieved, the clinical pregnancy rate per oocyte retrieval, the implantation rate and miscarriage rate. This result demonstrates that the association of rLH with rFSH may prevent any decrease in oestradiol after antagonist administration and that a significantly higher number of mature oocytes was available for laboratory work. Nevertheless, it failed to show any statistically significant difference in clinically significant end-points in IVF (implantation and pregnancy rates). Additional randomized controlled trials are needed to confirm these results further. © 2007 Published by Reproductive Healthcare Ltd.en
dc.description.affiliationCentre for Human Reproduction Prof. Franco J, Ribeirão Preto, SP
dc.description.affiliationDepartment of Gynaecology and Obstetrics Faculty of Medicine of Botucatu UNESP, Botucatu, SP
dc.description.affiliationFaculty of Medicine Santo Amaro University, São Paulo, SP
dc.description.affiliationUnespDepartment of Gynaecology and Obstetrics Faculty of Medicine of Botucatu UNESP, Botucatu, SP
dc.format.extent14-25
dc.identifierhttp://dx.doi.org/10.1016/S1472-6483(10)60758-4
dc.identifier.citationReproductive BioMedicine Online, v. 14, n. 1, p. 14-25, 2007.
dc.identifier.doi10.1016/S1472-6483(10)60758-4
dc.identifier.issn1472-6483
dc.identifier.scopus2-s2.0-33846503177
dc.identifier.urihttp://hdl.handle.net/11449/69439
dc.identifier.wosWOS:000243506300006
dc.language.isoeng
dc.relation.ispartofReproductive BioMedicine Online
dc.relation.ispartofjcr2.967
dc.relation.ispartofsjr1,343
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectGnRH antagonist
dc.subjectOvarian stimulation
dc.subjectRecombinant FSH
dc.subjectRecombinant LH
dc.subjectcetrorelix
dc.subjectchorionic gonadotropin
dc.subjectestradiol
dc.subjectgonadorelin antagonist
dc.subjectrecombinant follitropin
dc.subjectrecombinant luteinizing hormone
dc.subjectcell count
dc.subjectclinical protocol
dc.subjectclinical trial
dc.subjectcombination chemotherapy
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdata base
dc.subjectdrug dose increase
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug withdrawal
dc.subjecteffect size
dc.subjectestradiol blood level
dc.subjectevidence based medicine
dc.subjectfertilization in vitro
dc.subjecthormonal regulation
dc.subjecthuman
dc.subjectintracytoplasmic sperm injection
dc.subjectlow drug dose
dc.subjectmeta analysis
dc.subjectmonotherapy
dc.subjectmultiple cycle treatment
dc.subjectoocyte maturation
dc.subjectovulation induction
dc.subjectpregnancy rate
dc.subjectrandomized controlled trial
dc.subjectrisk assessment
dc.subjectsingle drug dose
dc.subjectspontaneous abortion
dc.subjectsystematic review
dc.subjectEstradiol
dc.subjectFemale
dc.subjectFertilization in Vitro
dc.subjectFollicle Stimulating Hormone
dc.subjectGonadotropin-Releasing Hormone
dc.subjectHumans
dc.subjectLuteinizing Hormone
dc.subjectOvulation Induction
dc.subjectPregnancy
dc.subjectPregnancy Rate
dc.subjectRandomized Controlled Trials
dc.subjectRecombinant Proteins
dc.subjectSperm Injections, Intracytoplasmic
dc.subjectTreatment Outcome
dc.titleRecombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: A meta-analysisen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Coleções

Artigos - Ginecologia e Obstetrícia - FMB